Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 10;65(4):1278–1292. doi: 10.1002/hep.28947

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 by the American Association for the Study of Liver Diseases

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Viral binding and replication in human cholangiocytes treated with TRTRVSRLY as a function of rotavirus strain. (A, B) Human cholangiocytes (H69) pretreated with 1 mM TRTRVSRLY peptide demonstrated significant decrease in RRV binding and replication. DGEA and GHRP are positive and negative controls, respectively. (C) The TRTRVSRLY peptide significantly inhibited the binding of only those strains that induce murine biliary atresia (RRV and GRV) with no effect on TUCH or Ro1845. (D) Similarly, RRV and GRV viral yields were significantly reduced, with no decrease in yield for TUCH or Ro1845. *P < 0.05 versus serum‐free media control.